The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Calcium acetate and magnesium carbonate (Osvaren®) has been rejected for the treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis). Although the product has been to reduce hyperphosphataemia associated with chronic renal disease the manufacturer did not present a sufficiently robust economic analysis.
Cannabinoid (Sativex®) has been rejected as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication. The manufacturer failed to make a submission.
Ethinylestradiol with drosperinone (Yasmin®) has been rejected for use as an oral contraceptive. The product has been shown to have similar contraceptive effectiveness to other combined oral contraceptives in routine use, with no significant differences in adverse event profile. The manufacturer did not present a sufficiently robust economic analysis.
Sevelamer carbonate (Renvela®) has been accepted for restricted use as second-line management in the control of hyperphosphataemia in adult patients receiving haemodialysis.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.